Logo Logo
Hilfe
Hilfe
Switch Language to English

Kretschmer, A.; Tolkach, Y.; Ellinger, J. und Kristiansen, G. (2017): Genetische Marker und Prognosefaktoren beim Prostatakarzinom. In: Urologe, Bd. 56, Nr. 7: S. 933-943

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

In the era of personalized medicine and precision oncology, innovative genetic biomarkers are of emerging interest to close the diagnostic and prognostic gap that is left by current clinicopathologic risk classifiers. The current review article summarizes evidence regarding prognostic and predictive genetic biomarkers that are currently in widespread clinical use at initial diagnosis as well as following definitive treatment of prostate cancer. We give a brief summary about basic principles of biomarker research studies and present current data for the Progensa PC3 test, TMPRSS2:ERG gene fusion, ConfirmMDx, Prolaris gene panel, OncotypeDX Genomic Prostate score, and Decipher classifier. Evidence regarding those genetic biomarkers has heavily increased recently. However, there is still a lack of large, multicentric and prospective clinical validation studies. Furthermore, comparative studies that investigate the prognostic value of various genetic biomarkers are needed.

Dokument bearbeiten Dokument bearbeiten